Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income (2016 - 2025)

Historic Net Income for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' Net Income fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
  • Northwest Biotherapeutics' Net Income amounted to -$16.9 million in Q3 2025, which was down 35.54% from -$16.6 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Net Income registered a high of -$11.7 million during Q3 2021, and its lowest value of -$22.5 million during Q2 2022.
  • Over the past 5 years, Northwest Biotherapeutics' median Net Income value was -$16.9 million (recorded in 2024), while the average stood at -$16.8 million.
  • The largest annual percentage gain for Northwest Biotherapeutics' Net Income in the last 5 years was 7818.48% (2021), contrasted with its biggest fall of 14848.66% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' Net Income (Quarter) stood at -$11.8 million in 2021, then tumbled by 64.0% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then dropped by 28.09% to -$21.0 million in 2024, then increased by 19.28% to -$16.9 million in 2025.
  • Its last three reported values are -$16.9 million in Q3 2025, -$16.6 million for Q2 2025, and -$18.9 million during Q1 2025.